ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

brincidofovir

Also written as “Brincidofovir”, “CMX001” and “SyB V-1901”.

Its studies are mostly in Adenoviridae Infections · Cytomegalovirus Infections · Lymphoma, T-Cell · Smallpox · Kidney Diseases, led by 3 companies.

Drug pageBrincidofovir: every studyAll 22 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 11, 201019 company-led studies, 1 open or runningNext primary completion: Jan 31, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jazz Pharmaceuticals140 open or runningphase 3since Jun 11, 2010Oct 23, 2008none ahead
SymBio Pharmaceuticalsits history only41 open or runningphase 3since Jan 20, 2026Aug 29, 2020Jan 31, 2028phase 3 · NCT07387367
Emergent BioSolutionsits history only10 open or runningphase 1since Jun 5, 2023Jun 5, 2023none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Jazz Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 23, 2008First study: phase 1 study in HealthyFirst studyNCT00780182 · 24 enrolled · United States
  2. Nov 17, 2008Phase 2 study in ViruriaNCT00793598 · 29 enrolled · United States
  3. Jul 17, 2009Phase 2 study in Cytomegalovirus InfectionsNCT00942305 · 239 enrolled · United States
  4. Jun 11, 2010Phase 3 study in Adenoviridae InfectionsNCT01143181 · 210 enrolled · United States
  5. Nov 12, 2010Phase 2 study in Adenovirus DiseaseNCT01241344 · 52 enrolled · United States
  6. Jun 30, 2011Phase 1 study in Hepatic ImpairmentNCT05391724 · 25 enrolled · United States
  7. Jan 14, 2013Phase 3 study in CMVNCT01769170 · 452 enrolled · United States, Belgium, Canada
  8. Mar 12, 2014Phase 3 study in Adenoviridae InfectionsNCT02087306 · 201 enrolled · United States
  9. Oct 7, 2014Phase 2 study in Ebola VirusNCT02271347
  10. May 7, 20152 phase 3 studies in Cytomegalovirus InfectionsNCT02439970, NCT02439957
  11. Nov 8, 2017Phase 2 study in Adenoviridae InfectionsNCT03339401 · 29 enrolled · United States, France, Germany and more
  12. Apr 26, 2018Phase 2 study in Adenoviridae InfectionsNCT03532035 · United States, Italy, Spain
  13. Feb 12, 2020Phase 2 study in Hemorrhagic Fever, EbolaNCT04268966

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“DNA polymerase inhibitor”ChEMBL 37, by rule

Studies

All 14 Jazz Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04268966Hemorrhagic Fever, Ebola2WithdrawnNov 20150
NCT03532035Adenoviridae Infections · United States, Italy, Spain2WithdrawnMay 10, 20190
NCT03339401Adenoviridae Infections · United States, France, Germany and more2TerminatedMay 10, 201929
NCT02439970Cytomegalovirus Infections · United States3TerminatedJan 30, 20165
NCT02439957Cytomegalovirus Infections · United States3TerminatedMay 15, 20166
NCT02271347Ebola Virus2WithdrawnJan 20150
NCT02087306Adenoviridae Infections · United States3CompletedJun 2016201
NCT01769170CMV · United States, Belgium, Canada3CompletedDec 2015452
NCT05391724Hepatic Impairment · United States1CompletedSep 201125
NCT01241344Adenovirus Disease · United States2CompletedJun 201352
NCT01143181Adenoviridae Infections · United States3CompletedDec 2012210
NCT00942305Cytomegalovirus Infections · United States2CompletedJan 2012239
NCT00793598Viruria · United States2CompletedOct 201029
NCT00780182Healthy · United States1CompletedDec 200824

How it is read

Names in the registry

  • “Brincidofovir”, 15 entries
  • “CMX001”, 3 entries
  • “SyB V-1901”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.